Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Breij · SciRah

Researcher profile · Semantic Scholar

E. Breij

Share profile

E. Breij — researcher profile on SciRah

h-index: 24
Works: 93
Citations: 2,997

Most-cited papers

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
M. Overdijk, S. Verploegen, M. Bögels, M. van Egmond +7 more
2015mAbs491 citations Open access
Semantic Scholar
Homogeneity of active demyelinating lesions in established multiple sclerosis
E. Breij, B. Brink, R. Veerhuis, C. van den Berg +5 more
2008Annals of Neurology369 citations
Semantic Scholar
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
J. Boshuizen, L. Koopman, O. Krijgsman, A. Shahrabi +16 more
2018Nature Medicine205 citations
Semantic Scholar
The Pathology of Multiple Sclerosis Is Location-Dependent: No Significant Complement Activation Is Detected in Purely Cortical Lesions
B. Brink, R. Veerhuis, E. Breij, P. van der Valk +2 more
2005Journal of Neuropathology and Experimental Neurology200 citations
Semantic Scholar
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
E. Breij, B. D. de Goeij, S. Verploegen, D. Schuurhuis +7 more
2014Cancer Research189 citations
Semantic Scholar
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
F. Da Roit, P. Engelberts, R. Taylor, E. Breij +6 more
2015Haematologica150 citations Open access
Semantic Scholar
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
P. Engelberts, I. Hiemstra, B. de Jong, D. Schuurhuis +12 more
2020EBioMedicine144 citations Open access
Semantic Scholar
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
B. D. de Goeij, T. Vink, H. ten Napel, E. Breij +4 more
2016Molecular Cancer Therapeutics116 citations Open access
Semantic Scholar
Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
J. Tromp, C. Geest, E. Breij, J. Elias +6 more
2011Clinical Cancer Research105 citations
Semantic Scholar
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
A. Muik, E. Garralda, I. Altıntaş, F. Gieseke +34 more
2022Cancer Discovery99 citations Open access
Semantic Scholar
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Hilma J. van der Horst, A. D. de Jonge, I. Hiemstra, Anne T. Gelderloos +9 more
2021Blood Cancer Journal72 citations Open access
Semantic Scholar
Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice
Paul A. Smith, N. Heijmans, B. Ouwerling, E. Breij +7 more
2005European Journal of Immunology67 citations Open access
Semantic Scholar
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
S. Oostindie, Hilma J. van der Horst, Laurens P. Kil, K. Strumane +14 more
2020Blood Cancer Journal62 citations Open access
Semantic Scholar
Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity
Maja Wållberg, J. Bergquist, A. Achour, E. Breij +1 more
2007European Journal of Immunology58 citations Open access
Semantic Scholar
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
S. Oostindie, Hilma J. van der Horst, M. Lindorfer, Erika M. Cook +13 more
2019Haematologica56 citations Open access
Semantic Scholar
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
L. Koopman, M. Terp, G. G. Zom, M. Janmaat +11 more
2019JCI Insight55 citations Open access
Semantic Scholar
Interactions between HIV-infected monocyte-derived macrophages and human brain microvascular endothelial cells result in increased expression of CC chemokines.
L. Boven, J. Middel, E. Breij, D. Schotte +3 more
2000Journal of Neurovirology51 citations
Semantic Scholar
A Role for Complement C5 in Organism Containment and Granulomatous Response during Murine Tuberculosis
J. K. Actor, E. Breij, R. A. Wetsel, H. Hoffmann +2 more
2001Scandinavian Journal of Immunology44 citations
Semantic Scholar
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, E. Gaglione, David Eik, J. Herrick +12 more
2023Blood Advances42 citations Open access
Semantic Scholar
Systematic study of tissue factor expression in solid tumors
J. de Bono, J. Harris, S. Burm, A. Vanderstichele +13 more
2022Cancer Reports40 citations Open access
Semantic Scholar
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
A. Muik, H. Adams, F. Gieseke, I. Altıntaş +20 more
2022Journal for ImmunoTherapy of Cancer38 citations Open access
Semantic Scholar
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
M. Overdijk, K. Strumane, F. Beurskens, Antonio Ortiz Buijsse +12 more
2020Molecular Cancer Therapeutics38 citations Open access
Semantic Scholar
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells
P. Engelberts, M. Voorhorst, J. Schuurman, T. van Meerten +9 more
2016Journal of Immunology38 citations Open access
Semantic Scholar
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
I. Hiemstra, K. Santegoets, M. Janmaat, B. D. de Goeij +16 more
2023EBioMedicine30 citations Open access
Semantic Scholar
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
Hilma J. van der Horst, Anne T. Gelderloos, M. Chamuleau, E. Breij +4 more
2021Blood Advances23 citations Open access
Semantic Scholar
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
A. Muik, I. Altıntaş, F. Gieseke, Kristina B Schoedel +17 more
2022Oncoimmunology20 citations Open access
Semantic Scholar
Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis
M. Vogt, C. E. Teunissen, E. Iacobaeus, D. A. M. Heijnen +5 more
2008Journal of Neurology Neurosurgery & Psychiatry20 citations Open access
Semantic Scholar
Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients.
E. Breij, P. Heijnen, A. van der Goes, C. E. Teunissen +2 more
2006Journal of Neuroimmunology18 citations
Semantic Scholar
Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
B. D. de Goeij, M. Janmaat, Grietje Andringa, Laurens P. Kil +10 more
2019Blood17 citations Open access
Semantic Scholar
The FcRgamma chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE.
E. Breij, P. Heijnen, R. Vloet, T. Saito +4 more
2005Journal of Neuropathology and Experimental Neurology16 citations Open access
Semantic Scholar
Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functionsin vitro
S. Alley, J. Harris, Anthony T. Cao, Elke Gresnigt-van den Heuvel +5 more
2019Experimental and Molecular Therapeutics14 citations
Semantic Scholar
Interactions between major histocompatibility complex class II surface expression and HIV: implications for pathogenesis
W. Kamp, E. Breij, H. Nottet, M. Berk
2001European Journal of Clinical Investigation12 citations
Semantic Scholar
An antibody-drug conjugate directed to tissue factor shows preclinical anti-tumor activity in head and neck cancer as a single agent and in combination with chemoradiotherapy.
J. Bakema, Marijke Stigter-van Walsum, Jeffrey R. Harris, S. Ganzevles +7 more
2023Molecular Cancer Therapeutics11 citations
Semantic Scholar
Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.
E. Breij, S. Verploegen, A. Lingnau, E. N. van den Brink +5 more
20159 citations
Semantic Scholar
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
Hilma J. van der Horst, S. Oostindie, S. Cillessen, Anne T. Gelderloos +6 more
2020HemaSphere8 citations Open access
Semantic Scholar
Abstract 2391: DR5 agonist activity of HexaBody®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models
M. Overdijk, K. Strumane, A. O. Buijsse, C. Vermot-Desroches +11 more
2019Immunology8 citations
Semantic Scholar
Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC
L. Koopman, M. Janmaat, Kirstine Jacobsen, M. Terp +6 more
2018Experimental and Molecular Therapeutics8 citations
Semantic Scholar
No association of Fc gamma RIIa, Fc gamma RIIIa and Fc gamma RIIIb polymorphisms with MS.
E. Breij, W. Ludo van der Pol, L. V. van Winsen, M. Jansen +3 more
2003Journal of Neuroimmunology8 citations
Semantic Scholar
Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies
S. Oostindie, M. F. Alemdehy, M. Janmaat, J. Meerding +6 more
2022Blood7 citations Open access
Semantic Scholar
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
K. Kemper, E. Gielen, P. Boross, M. Houtkamp +12 more
2022Life Science Alliance5 citations Open access
Semantic Scholar
Abstract 1574: Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas
Christopher Chiu, I. Hiemstra, W. ten Hagen, R. Snijdewint-Nkairi +10 more
2021Immunology5 citations
Semantic Scholar
Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding
Hilma J. van der Horst, M. Overdijk, E. Breij, M. Chamuleau +2 more
20175 citations
Semantic Scholar
Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies
I. Hiemstra, P. Engelberts, B. de Jong, D. Schuurhuis +12 more
2018Blood4 citations
Semantic Scholar
Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus.
S. J. Merat, D. van de Berg, C. Bru, E. Yasuda +9 more
2017JIM - Journal of Immunological Methods4 citations
Semantic Scholar
Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
A. Spencer, K. F. Iversen, B. Dhakal, M. Creignou +13 more
2022Blood3 citations Open access
Semantic Scholar
Antibodies as drugs–a Keystone Symposia report
J. Cable, E. Saphire, A. Hayday, T. Wiltshire +27 more
2022Annals of the New York Academy of Sciences3 citations Open access
Semantic Scholar
PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS
C.-W. Chiu, I. Hiemstra, W. ten Hagen, R. Snijdewint-Nkairi +13 more
2021Hematological Oncology3 citations
Semantic Scholar
561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation
A. Muik, I. Altıntaş, Rachelle E. Kosoff, F. Gieseke +13 more
20203 citations Open access
Semantic Scholar
Use of an antibody-drug conjugate targeting tissue factor to induce complete tumor regression in xenograft models with heterogeneous target expression.
E. Breij, D. Satijn, S. Verploegen, B. D. de Goeij +4 more
20133 citations
Semantic Scholar
Surfactant protein D/anti-Fc receptor bifunctional proteins as a tool to enhance host defence.
E. Breij, J. J. Batenburg
2008Expert Opinion on Biological Therapy3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Parren×16
Invite
P. Parren — researcher profile on SciRah
D. Satijn×13
Invite
D. Satijn — researcher profile on SciRah
T. Mutis×9
Invite
T. Mutis — researcher profile on SciRah
M. Janmaat×8
Invite
M. Janmaat — researcher profile on SciRah

×8

Invite

I. Hiemstra — researcher profile on SciRah

Invite

A. Sasser — researcher profile on SciRah

Invite

M. Overdijk — researcher profile on SciRah

S. Verploegen×7

Invite

S. Verploegen — researcher profile on SciRah

D. Schuurhuis×7

Invite

D. Schuurhuis — researcher profile on SciRah

J. Schuurman×7

Invite

J. Schuurman — researcher profile on SciRah

Invite

T. Ahmadi — researcher profile on SciRah

B. D. de Goeij×6

Invite

B. D. de Goeij — researcher profile on SciRah